A new study has found that many people who take GLP-1 drugs, such as semaglutide and tirzepatide, do not take them consistently. Instead, they often stop and then restart the medication, creating a pattern that researchers call “intermittent use.” This finding comes from an analysis of prescription data and highlights a key challenge in managing long-term conditions like obesity and type 2 diabetes.

Key takeaways

  • About half of patients starting a GLP-1 drug stopped within one year, according to the study.
  • Many who stopped later resumed the medication, leading to a stop-start cycle.
  • Reasons for stopping may include side effects, cost, or lack of perceived results.
  • The pattern raises concerns about whether patients receive the full benefits of sustained treatment.

What the study found about GLP-1 drug use

The research, which was reported by News-Medical, examined prescription records for GLP-1 receptor agonists. These drugs are widely used for weight management and blood sugar control in diabetes. The analysis showed that a substantial portion of patients did not remain on the therapy continuously. Many stopped taking the medication within the first year, but a notable number later returned to it. This pattern of starting, stopping, and restarting was more common than continuous long-term use.

The study did not specify the exact percentage of patients who followed this pattern, but it described the behavior as “frequent.” The findings suggest that adherence to GLP-1 therapy may be lower than what is typically seen with other chronic medications, according to the report.

Why patients might stop and restart GLP-1 drugs

There are several possible reasons why patients might not stay on GLP-1 drugs consistently. Side effects such as nausea, vomiting, or diarrhea are common, especially when starting the medication. These symptoms can lead some people to stop early. Other factors include the high cost of these drugs, which can be a barrier for those without insurance coverage. Some patients may also stop if they feel the medication is not working as expected or if they reach a temporary goal.

The stop-start pattern may also reflect the way these drugs are prescribed. Doctors sometimes recommend a break if side effects are severe, or patients may decide on their own to pause treatment. The study did not investigate individual motivations but noted that the pattern is widespread.

Implications for treatment and health outcomes

Intermittent use of GLP-1 drugs could affect how well they work. These medications are designed to be taken consistently to maintain weight loss or blood sugar control. When patients stop, they may regain weight or see blood sugar levels rise. Restarting later might not be as effective if the body has adapted to the break, the study suggested.

Healthcare providers may need to discuss adherence more openly with patients. Understanding why people stop could help doctors offer solutions, such as adjusting the dose or managing side effects better. The findings also point to a need for more support for patients starting these therapies.

Frequently Asked Questions

How common is it to stop taking GLP-1 drugs?

The study found that about half of patients stop taking the medication within the first year of starting. This rate is higher than for many other chronic medications, indicating that adherence is a significant issue with GLP-1 drugs.

Does stopping GLP-1 drugs cause weight regain?

Yes, weight regain is common after stopping GLP-1 drugs. The medications help suppress appetite and regulate metabolism, and when they are discontinued, many people experience a return of appetite and gradual weight gain. This is one reason why consistent use is often recommended.

What should I do if I want to stop taking a GLP-1 drug?

If you are considering stopping a GLP-1 medication, talk to your doctor first. They can help you weigh the benefits and risks, and may suggest a plan to taper off or address any side effects. Stopping abruptly without guidance can lead to unwanted changes in weight or blood sugar.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.